Firma ViGeneron, Autor bei PR-Web

Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron´s REVeRT technology

Posted on 25. October 202326. October 2023 by Firma ViGeneron Posted in Research / Development Tagged aav, abca4, brain, crispr, packaging, patients, pigmentosa, retinal, retinitis, stargardt, trans, vg801, vg901, vigeneron, with

REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packaging size in various tissues Potential to address prevalent inherited diseases caused by larger genes such as Stargardt disease Delivery of CRISPR […]

ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT

Posted on 11. October 202211. October 2022 by Firma ViGeneron Posted in Research / Development Tagged aav, cell, cells, packaging, patients, pigmentosa, retinal, retinitis, stargardt, trans, vg901, vgaav, vigeneron, vigenerons, with

Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development ViGeneron GmbH, a next-generation gene therapy company, today announced […]

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

Posted on 26. April 202226. April 2022 by Firma ViGeneron Posted in General Tagged cells, daiichi, financial, injection, new, patients, research, retinal, sankyo, therapy, treatment, vgaav, vigeneron, vigenerons, with

ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye […]

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

Posted on 6. April 2022 by Firma ViGeneron Posted in Research / Development Tagged aav, cells, clinical, cns, injection, ophthalmic, patients, payment, retinal, royalties, therapy, vgaav, vigeneron, vigenerons, with

Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, […]

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

Posted on 18. January 202112. April 2021 by Firma ViGeneron Posted in Research / Development Tagged cells, collateral, daiichi, financial, injection, medical, ophthalmic, patients, research, sankyo, therapy, treatment, vigeneron, vigenerons, with

ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a […]

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

Posted on 5. January 202112. April 2021 by Firma ViGeneron Posted in General Tagged aav, cells, clinical, medical, patients, payment, poc, research, retinal, royalties, therapy, vgaav, vigeneron, vigenerons, with

. – Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target – The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections […]

ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

Posted on 1. December 202012. April 2021 by Firma ViGeneron Posted in General Tagged aav, apptec, atu, cell, cells, market, ophthalmic, patients, pigmentosa, retinal, retinitis, vgaav, vigeneron, vigenerons, with

ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), today announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy […]